Abstract
Operative breast cancers were subjected to a serological and immunohistochemical evaluation of sialyl Lewisx antigen as a tumor-associated one, where a new monoclonal antibody CSLEX1 which reacts with sialyl Lewisx antigen was used. Percent positive of sailayl Lewisx in sera of 30 patients with breast cancer was 30%(9/30), which was better than those of any other tumor markers such as CEA, CA19-9, CA15-3 and SLX. Percent positives, according to clinical stages, were 20.0%, 37.5%, 40.0% and 50.0% in stage I, II, III and IV respectively. Immunohistochemically, the expression of a sialyl Lewisx in the normal ductal epithelium and carcinoma cells of 41 breast cancers demonstrated 95.5%(21/22) and 65.9%(27/41) respectively. Although the immunohistochemical experssion of sialyl Lewisx antigen indicated a low cancer specificity, comparatively high positive rates in stage I and II were obtained in sera of cancer patients. It has been suggested that sialyl Lewisx antigen is useful as a tumor-associatd antigen in breast cancers.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callMore From: The journal of the Japanese Practical Surgeon Society
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
